SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Byström M.)
 

Sökning: WFRF:(Byström M.) > (2015-2019) > Treatment outcome 6...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005441naa a2200397 4500
001oai:DiVA.org:oru-98966
003SwePub
008220511s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-989662 URI
040 a (SwePub)oru
041 a engb eng
042 9 SwePub
072 7a vet2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Holmberg, M.u University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Stockholm, Sweden; Karolinska University Hospital, ANOVA, Stockholm, Sweden4 aut
2451 0a Treatment outcome 6-10 years after diagnosis of hyperthyroidism in 2916 patients :b a longitudinal evaluation of a swedish incidence cohort
264 1b Mary Ann Liebert,c 2018
338 a print2 rdacarrier
520 a Treatment of Graves’ disease (GD) and toxic nodular goiter (TNG) has the objectives to cure hyperthyroidism, prevent recurrent disease and preserve thyroid function. Treatment efficacies and long-termout comes of antithyroid drugs (ATD), radioactive iodine (RAI) or surgery varies in the literature. We report outcome of treatment, cure rate and risk factors for relapse for GD and TNG in an unselected cohort. A prospective incidence-cohort of de novo diagnosed GD and TNG patients (n = 2916) from 2003-05, were invited to a follow-up 6 - 10 years after diagnosis. Questionnaires were sent to 2430 patients regarding treatments, cure rate, recurrence, quality of life, demographic data, comorbidities and life-style factors. Patients were treated according to clinical routine with ATD, RAI or surgery. Of those included, 1186 (83.3%) had GD and 237 (16.7%) had TNG. In GD patients, 351 (45.3%), 264 (81.5%), and 52 (96.3%) were cured by ATD, RAI or surgery respectively as first line treatment. Of those, 77.0%, 15.4% and 3.8% respectively were without levothyr-oxine supplementation at follow-up at 8 – 0.9 years. Including all treatment modalities, 851 (71.8%) of GD patients were cured within one treatment period. At follow-up, 278 (23%) of GD patients had been operated. In TNG patients, RAI cured 88.6% and surgery 92.9%, whereof 52/154 (33.8%) and 3/15 (20%) had no levothyroxine supplementation post RAI and surgery, respectively.The proportion that did not feel fully recovered at follow-up was 25.3% of GD and 18.1% of the TNG patients. Overall, treatment of hyperthyroidism results in preserved thyroid function only in 35.3% and 44.7% of GD and TNG cases, respectively. As many as 23.4% of the GD patients end up with surgery although only 4.6% choose it from the beginning. Our treatment tradition cures 71.8% of GD patients and 78.1% of TNG patients within one treatment period. The high number of patients who do not feel recovered 6 -10 years after hyperthyroidism in GD and TNG is are minder of the chronic nature of hyperthyroidism.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
7001 a Sjölin, Gabriel,d 1979-u Örebro University Hospital, Faculty of Medicine and Health, Örebro, Sweden4 aut0 (Swepub:oru)glsn
7001 a Byström, Kristina,d 1961-u Department of Medicine, Örebro University Hospital, Örebro, Sweden4 aut0 (Swepub:oru)kbm
7001 a Khamisi, S.u Deparment of Medical Sciences, Uppsala University, Uppsala, Sweden; Department of Medicine, Uppsala University Hospital, Uppsala, Sweden4 aut
7001 a de Laval, D.u Department of Medicine, Blekinge Hospital, Karlskrona, Sweden4 aut
7001 a Abraham-Nordling, M.u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Calissendorff, J.u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden4 aut
7001 a Lantz, M.u Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Endocrinology, Skåne University Hospital, Malmö, Sweden4 aut
7001 a Hallengren, B.u Department of Clinical Sciences, Lund University, Lund, Sweden; Department of Endocrinology, Skåne University Hospital, Malmö, Sweden4 aut
7001 a Filipsson Nyström, H.u University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Stockholm, Sweden; Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut
7001 a Törring, O.u Institution for Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Internal Medicine, Södersjukhuset, Stockholm, Sweden4 aut
7001 a Wallin, Göran,d 1952-u Örebro University Hospital, Faculty of Medicine and Health, Örebro, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden4 aut0 (Swepub:oru)gwn
7102 a University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Stockholm, Sweden; Karolinska University Hospital, ANOVA, Stockholm, Swedenb Örebro University Hospital, Faculty of Medicine and Health, Örebro, Sweden4 org
7730 t Thyroidd : Mary Ann Liebertg :S1q :S1x 1050-7256x 1557-9077
8564 u https://doi.org/10.1089/thy.2018.29065.abstracts
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-98966

Hitta via bibliotek

  • Thyroid (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy